Evidence map›Paper›PMID 30101405›Full record

ReviewCellular and molecular life sciences : CMLS2018

Implication of gut microbiota metabolites in cardiovascular and metabolic diseases.

Francois Brial, Aurélie Le Lay, Marc-Emmanuel Dumas, Dominique Gauguier

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Francois BrialSorbonne University, University Paris Descartes, INSERM UMR_S1138, Cordeliers Research Centre, 15 rue de l'Ecole de Médecine, 75006, Paris, France.
Aurélie Le LaySorbonne University, University Paris Descartes, INSERM UMR_S1138, Cordeliers Research Centre, 15 rue de l'Ecole de Médecine, 75006, Paris, France.
Marc-Emmanuel DumasSection of Biomolecular Medicine, Division of Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, London, UK.
Dominique GauguierSorbonne University, University Paris Descartes, INSERM UMR_S1138, Cordeliers Research Centre, 15 rue de l'Ecole de Médecine, 75006, Paris, France. dominique.gauguier@inserm.fr.ORCID http://orcid.org/0000-0001-6156-9530

Funding

European Commission HEALTH-F4-2012-305312
6 · The paper itself

Abstract

Evidence from the literature keeps highlighting the impact of mutualistic bacterial communities of the gut microbiota on human health. The gut microbita is a complex ecosystem of symbiotic bacteria which contributes to mammalian host biology by processing, otherwise, indigestible nutrients, supplying essential metabolites, and contributing to modulate its immune system. Advances in sequencing technologies have enabled structural analysis of the human gut microbiota and allowed detection of changes in gut bacterial composition in several common diseases, including cardiometabolic disorders. Biological signals sent by the gut microbiota to the host, including microbial metabolites and pro-inflammatory molecules, mediate microbiome-host genome cross-talk. This rapidly expanding line of research can identify disease-causing and disease-predictive microbial metabolite biomarkers, which can be translated into novel biodiagnostic tests, dietary supplements, and nutritional interventions for personalized therapeutic developments in common diseases. Here, we review results from the most significant studies dealing with the association of products from the gut microbial metabolism with cardiometabolic disorders. We underline the importance of these postbiotic biomarkers in the diagnosis and treatment of human disorders.

Indexed as

BiomarkersCardiovascular DiseasesGastrointestinal MicrobiomeHumansMetabolic DiseasesBiomarkersAnimal modelsComplex diseasesGut microbiomeMetabolic modelingMetabolic networksMetabolomicsMicrobiotaSymbiotic bacterial systemsTransgenomic interactions

Identifiers

PMID30101405
PMCPMC6182343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.